氨酸激酶抑制剂用于湿湿的与年龄相关的黄斑变性:当前的发展格局
1Drexel University College of Medicine, Philadelphia, Pennsylvania.
氨酸激酶抑制剂 (TKIs) 通过向异常的血管生长,显示出有前途的治疗湿血与年龄相关的黄斑变性 (AMD). 与目前的治疗方法相比,这些药物可以提供更好的疗效和减少治疗负担.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是老年人视力丧失的主要原因.
- 神经血管 (湿) AMD涉及由VEGF和其他途径驱动的异常血管生长.
- 目前的抗VEGF治疗需要频繁注射,这给患者带来了挑战.
研究的目的:
- 审查氨酸激酶抑制剂 (TKIs) 在治疗湿 AMD 中的新兴作用.
- 突出临床发展和技术知识的潜在优势,比现有疗法.
- 讨论湿性AMD的未来治疗环境.
主要方法:
- 审查当前文献和临床试验数据的TKIs湿湿的AMD.
- 对TKI机制,疗效,安全和治疗负担的分析.
- 技术知识与标准抗VEGF疗法的比较.
主要成果:
- 试管婴儿提供血管新生通路的细胞内向,可能导致更长的耐用性.
- 多个TKI候选者正在通过III期临床试验.
- 技术技能可以减少与频繁的眼内注射相关的治疗负担.
结论:
- 技术知识构成一个有前途的下一代湿性AMD治疗类.
- 需要进一步的研究来确认与抗VEGF疗法相比的长期疗效和安全性.
- 技术知识有潜力显著改变湿 AMD 的治疗范式.
更多相关视频
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
相关概念视频
Receptor Tyrosine Kinases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Introduction to Developmental Psychology
